Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Since the "merger" was completed over a month before the filing period there should have been a breakout of profits and expenses from L4L. There weren't any which is to be expected when a ghost company merges into a shell company.
Offhand, the only things that would lead to a negative outcome would be that the patient has the CCR5 delta32 gene deletion (in which case leronlimab does nothing), they are very near organ failure or the fibrosis is so advanced there's no recovery.
From what we know of the first four patients it seems unlikely any of the 10 fit that criteria.
I think we're in an echo chamber. The investors must be sleeping off the hangover they have from drinking to forget.
Just think of the happy faces on investors here when the price hits .0001. Oh how many shares they'll be able to buy then.
Leronlimab and Sepsis
Someone here was asking if leronlimab would treat sepsis.
The short answer, yes it will.
Sepsis is caused by a fast massive immune system response causing an even larger regulatory response.
That massive immune response is typified by rapidly rising TNF (tumor necrosis factor) levels causing a drastic rise of IL-6 (interleukin-6). The regulatory response of TREGS (regulatory t-cells) causes NKT (natural killer t-cell) counts to drop crashing out the immune system. This allows virus or bacteria to destroy unchecked.
Leronlimab downregulates TNF and IL-6 so the initial immune response stays in check. It also increases NKT production and decreases TREG production through macrophage differentiation, boosting the immune system while putting a curb on controls.
Current filings and a name change which should have happened months ago but never will.
But he's averaging down. Better to lose $3700 and have a million shares then to lose $870 and only have 100 thousand shares.
With such a small patient population we would only get a small indication based on how fast there's fluid reduction in the lungs, how fast oxygen levels increase and the speed of recovery compared to regular patients.
Do any of them concern using camel dung to cure dysentery?
The leronlimab trial for COVID-19 is 6 weeks. Preliminary means something taking place before the event in question happens.
We should have preliminary results on leronlimab fairly soon after China starts their trials.
We need John Bercow.